Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Delorazepam is a benzodiazepine derivative characterized by anxiolytic, sedative, muscle relaxant, hypnotic, and anticonvulsant properties. Its mechanism of action involves acting as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor, thereby enhancing the binding of the inhibitory neurotransmitter GABA. This leads to an increased influx of chloride ions into neurons, resulting in hyperpolarization and reduced neuronal excitability. Delorazepam is primarily indicated for the short-term management of severe anxiety disorders, as a premedication before surgical or diagnostic procedures, and in the treatment of alcohol withdrawal. It exhibits a long elimination half-life, typically ranging from 80 to 115 hours, and is metabolized in the liver.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Delorazepam.